SLS stock forecast, quote, news & analysis
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications... Show more
Why Is SELLAS Life Sciences Group, Inc. (SLS) Stock Down -19.52% Today?
Key Takeaways
- SLS shares plunged approximately 19.5% in today’s session, closing near $7.22 after the prior session’s close of $8.97.
- No single company-specific news event triggered the decline; the move reflects typical volatility in a pre-readout biotech stock.
- Profit-taking after a sharp multi-month rally appears to be the dominant near-term driver.
- Broader biotech sector weakness and rotation out of high-beta names contributed to the pressure.
- Traders are now focused on the 80th event in the pivotal Phase 3 REGAL trial of galinpepimut-S in AML and any updates from upcoming investor conferences.
Opening Summary
SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing novel immunotherapies and targeted treatments for cancer, with its lead asset galinpepimut-S (GPS) in a pivotal Phase 3 trial for acute myeloid leukemia (AML). The stock fell sharply today, declining 19.52% to close at approximately $7.22 from the previous session’s close of $8.97. The decline occurred without any fresh corporate announcements, pointing instead to post-rally consolidation in a volatile clinical-stage name.
Profit-Taking Following Recent Gains
SLS had advanced substantially in recent months on anticipation of the REGAL trial readout and positive Phase 2 data for SLS009. With the stock trading near multi-year highs, investors appear to have taken profits ahead of the binary outcome expected when the trial reaches its 80th event. Such pullbacks are common in pre-data biotech equities that have already priced in significant upside.
Broader Biotech Sector Pressure
The selloff aligned with weakness across small-cap biotechnology names, where sentiment has softened amid macroeconomic uncertainty and reduced risk appetite. High-beta clinical-stage stocks often experience amplified moves on days when the broader sector rotates lower, even in the absence of company-specific headlines.
Market Context and Trading Activity
Volume remained elevated relative to recent averages, consistent with heightened retail and institutional activity around the name. The decline pushed SLS below several short-term moving averages but left it well above key longer-term support levels established during the prior uptrend. The move diverged from major indices, which traded modestly lower, underscoring SLS’s standalone volatility rather than a market-wide event.
Trending AI Robots
Trending AI Robots showcases Tickeron’s highest-performing AI trading bots under current market conditions. The platform offers hundreds of AI-driven strategies across thousands of tickers, each varying by timeframe, risk parameters, and performance metrics. Only bots demonstrating the strongest results in today’s environment are featured in this curated section. Investors seeking systematic approaches to volatile names like SLS can explore the live list of trending bots for additional perspective.
What Comes Next for SLS
Attention remains squarely on the REGAL Phase 3 trial, where final analysis will follow the 80th event. Additional data from the ongoing Phase 2 study of SLS009 in AML and participation in upcoming investor conferences, including the TD Cowen Oncology Innovation Summit, may provide incremental updates. As with any clinical-stage biotech, risks include trial delays, regulatory feedback, and potential dilution. Investors should monitor cash position updates and any partnership or financing activity for further context.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SLS's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for SLS moved out of overbought territory on June 02, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SLS turned negative on June 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SLS broke above its upper Bollinger Band on May 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on SLS as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 126 cases where SLS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.625) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). SLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology